Razoxane (ICRF 159) in the treatment of psoriasis.
This paper describes our experience with the use of razoxane (ICRF 159), a new anti-mitotic drug, in the treatment of thirty-six patients with severe psoriasis. The drug has proven highly effective both in cutaneous and in arthropathic disease. The drug is well tolerated by patients and appears to be free of hepatotoxicity. However, it causes depression of the neutrophil leukocyte count, an effect which is entirely dose-dependent; the hazard to patients can be minimized by careful supervision of therapy.
D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D000740:Anemia / Q000139:chemically induced; D001168:Arthritis / Q000188:drug therapy / Q000209:etiology; D001855:Bone Marrow Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010879:Piperazines / Q000627:therapeutic use*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*
D010879:Piperazines; D011929:Razoxane